Diagnostic and therapeutic updating on invasive fungal infection - From old clichés to new evidence;Actualización diagnóstica y terapéutica en infecciones fúngicas invasoras: De los antiguos tópicos a las nuevas evidencias

Farmacia Hospitalaria

Volumn 25, Issue 6, 2002, Pages 345-355

  Gallego Luque, C P ^a   De la Torre Cisneros, Julián ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Amphotericin; Azoles; Diagnosis; Fungal infection; Treatment

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; KETOCONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIGEN DETECTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; MYCOSIS; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; REVIEW; SIDE EFFECT; SURGICAL DRAINAGE;

EID: 18344417303     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Diagnosis and treatment of oportunistic infections in immunocompromised surgical patients
2. Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis and management
3. Infections disease pathology and emerging infections? Are we prepared?
4. The new fungal opportunistic are coming
5. Uncommon opportunistic fungi: New nosocomial threats
6. Lukemia, lynphoma and myeloma
7. Therapy of infection in patients with granulocytopenia
8. Empiric antimicrobial therapy for the febrile granulocytopenic cancer patients: Lessons from ORTC trials
9. New perspectives in the diagnosis of systemic fungal infections
10. Clinical presentation of infection in granulocytopenic patients
11. Epidemology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
12. The value of fungal surveillance clutures as predictors of sistemic fungal infections
13. Opportunistic funfal infection among cancer patients
14. Current trends in immunodiagnosis of candidiasis and aspergillosis
15. Candida dubliniensis sp.: Phenotypic and molecular characterizacion of a novel especies associated with oral candidiasis in VIH infected individuals
16. Candida dubliniensis, aproximación a su diagnóstico
17. Candia Cryptococcus and other yeasts of medical importance 1184-1200
18. Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocitopenia
19. Opostinistic fungal infections in patients with leukemia and linphoma
20. Novedades en el diagnóstico de las infecciones fúngicas
21. Simplified adsortion method for detection of antibodies to Candida albicans
22. Latex aglutination test for detection of Candida antigen in patientes with disseminated disease
23. Diagnosis of invasive candidiasis by detection of mannan antigen by using the avidin-voitin enzyme immunoassay
24. Diagnosis of systemic candidiasis by latex aglutination for serum antigen
25. Detection of circulating Candida enolasa by immunoassay in patients with cancer and invasive candidiasis
26. Rate of arabinitol production by pathogenic yeast especies
27. Aspergillus fumigatus and aspergillosis
28. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation
29. Theraputic outcome in invasive aspergillosis
30. Open lung biopsy diagnosis of diffuse pulmonar infiltrates after marrow transplantation
31. The use of respiratory-tract cultures in the diagnosis of the invasive pulmonary asprgillosis
32. Invasive aspergillosis
33. Galactomannan antigenemia in invasive aspergillosis
34. Sandwich enzyme-linked immunoabsorbent assay compared with Pastored latex agglutination test for diagnosing invesive aspergillosis in immunocompromised patients
35. Aspergillus infection: Problems in diagnosis and treatment
36. Detection and diferentiation of fungi in clinical specimens using pdymerase chain reaction (PCR) amplification and restriction enzyme analysis
37. Microtitration plate enzyme immunoassay to detect PCRamplified DNA from Candida species in blood
38. Detection of Aspergillus fumigatus by PCR
39. The detection of Aspergillus spp. by the polymerase chain reaction and its evaluation in brochoalveolar lavage fluid
40. General primer-mediated PCR for detection of Aspergillus
41. Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR
42. Detection and identification of fungal pathogens in blood by using molecular probes
43. PCR detection of DNA specific for Aspergillus species in serum of patients with invasive aspergillosis
44. Evaluation of PCR for detection of DNA specific for Aspergillus species in sera of patients with various forms of pulmonary aspergillosis
45. PCRELISA for the early diagnosis of invasive pulmonary aspergillosis infection in neutropenic patients
46. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
47. Prolonged granulocytopenia: The mayor risk factor for invasive aspergillosis in patients with acute leukemia
48. Clinical aspects of fungal infection in organ transplant recipients
49. Invasive fungal infections in renal transplant recipients
50. Non-candida fungal infections after bone marrow transplantation: Risk factors and outcome
51. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
52. Empiric antifungal therapy in granulocitopenic patients
53. Amphotericin B vs high-dose ketokonazol for empirical antifungal therapy among febrile, granulocytopenic cancer patients: A prospective, randomized estudy
54. Clinical value of empirical anfotericina B in patients with acute myelogenous leukemia
55. Aspergillus fumigatus and aspergillosis
56. Lipid formulations of amphotericin B: Recent progress and future directions
57. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
58. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
59. Introduction to antifungal drugs
60. Development of fluconazole resistance in Candida albicans causing disseminated infection in patient undergroing marrow transplantation
61. Overview of oral azole drugs as systemic antifungal therapy
62. Use of azoles for systemic antifungal therapy
63. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species
64. Vorizonazol for the treatment of S.apiospermun and S.prolificans infection
65. Amphotericin B resistant filamentous fungi: Fusaruim, Pseudoallescheria, and other tenacious moulds
66. Granulocyte colony-stimulating factor and other cytokines in antifungal therapy
67. Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia
68. A randomized, double-blind, placebo-controlled, phase III study of Filgrastin in remission induction and consolidation therapy for adults with de novo acute myeloid leukaemia
69. A double-blind, randomized, placebo-controled phase II study of filgrastin (recombinant granulocyte colony-stimulating factor) in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients
70. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: Effects of granulocyte colony stimulating factor and granulocyte-maaophage colony-stimulating factor
71. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyted derived macrophages and synergy with fluconazde
72. Protective effect of human granulocyte colony-stimulating factor on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice
73. Protective effect of human granulocyte colony-stimulating factor on Candida infections in normal and immunosuppressed mice
74. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients
75. Current status of granulocyte (neutrphil) transfusion therapy for infectious disease
76. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and a review
77. Enviromental surveillance and other measures in the prevention fo nosocomial fungal infections
78. Use the macrophage colony-estimulating factor in the treatment of fungal infections
79. Fungemia in the immunocompromised host: Changing patterns, antigenemia, high mortality
80. A controled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation